Welcome to our dedicated page for THERIVA BIOLOGICS news (Ticker: TOVX), a resource for investors and traders seeking the latest updates and insights on THERIVA BIOLOGICS stock.
Theriva Biologics Inc (TOVX) is a clinical-stage biotechnology company pioneering oncolytic adenovirus therapies designed to degrade tumor stroma and enhance cancer treatment efficacy. This page provides official updates on clinical developments, research breakthroughs, and strategic initiatives.
Investors and researchers will find a comprehensive collection of press releases, trial result announcements, and regulatory updates related to VCN-01 and other pipeline candidates. Our curated news feed focuses on mechanistically driven advancements in addressing pancreatic, ocular, and other hard-to-treat cancers.
Key updates include progress in systemic delivery methods, partnerships with leading oncology research institutions, and preclinical-to-clinical transition milestones. All content is verified through primary sources to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for timely access to validated information about Theriva Biologics' innovative approach to overcoming treatment resistance through tumor microenvironment modification. Check regularly for new developments in this cutting-edge area of cancer therapeutics.
Theriva™ Biologics, a clinical-stage company, reported positive results from a Phase 1 trial for VCN-01 in pediatric patients with retinoblastoma and presented preclinical data on VCN-01's potential in pancreatic cancer treatment. The Phase 2b trial for VCN-01 in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) is expected to complete enrollment soon. The company has $18.3 million in cash as of March 31, 2024, providing runway into Q1 2025.
FAQ
What is the current stock price of THERIVA BIOLOGICS (TOVX)?
What is the market cap of THERIVA BIOLOGICS (TOVX)?
